Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.83 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.83 |
| ▸ | PGR | P06401 | 4/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | AR | P10275 | 3/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.65 |
| ▸ | SHBG | P04278 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10597451 | 0.93 | NR3C2 (0.87) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL10597455 | 0.93 | NR3C2 (0.87) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL29060653 | 0.92 | NR3C2 (0.86) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL221482 | 0.92 | NR3C2 (0.86) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL14936050 | 0.91 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL11209085 | 0.91 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL14339600 | 0.91 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL14473210 | 0.91 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL21111521 | 0.91 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL111478 | 0.91 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7284 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260091042-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | ANTARES PHARMA, INC. (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-12521404-B2 | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | ANTARES PHARMA, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2025264805-A2 | SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4618933-A1 | SYSTEMS, METHODS, AND APPARATUSES FOR DRUG INJECTORS | SOLUtion Medical, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-12419831-B2 | Hydrocortisone oral liquid formulations | ETON PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |
| EP-0740528-A4 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP (US) | 1998-04-01 | — | — | EP | claimed |
| US-5733572-A | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles | IMARX PHARMACEUTICAL CORP. (US) | 1998-03-31 | — | — | US | claimed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | claimed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
| US-4747845-A | POLYACRYLATES OR POLYACRYLAMIDE WITH SOLVENT AND HYDROGEN BONDING PLASTICIZER | ENQUAY PHARMACEUTICAL ASSOCIATES (US) | 1988-05-31 | — | — | US | claimed |
| US-4304765-A | Ocular insert housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1981-12-08 | — | — | US | claimed |
| US-3981398-A | Aid in the management of clinical emergencies in medical and dental practices and other circumstances | Pienaar, Hendrik Lukas (ZA) | 1976-09-21 | — | — | US | claimed |